Medical device company Hemovent GmbH reported on Monday the receipt of the CE marking for its MOBYBOX Runner Controller, to market the product throughout the heart and lung support market in the EU.
The company said the Runner is designed to slingshot clinicians into a new era of mobility and ease of use. The device is designed for Extracorporeal Life Support (ECLS) applications, including Extracorporeal CardioPulmonary Resuscitation (ECPR) to treat patients in cardiac arrest or profound circulatory shock.
Following the Runner EU regulatory approval, the company has created an entirely new solution for the extreme challenges of ECLS deployment in situations with unpredictable and severely restricted emergency environments, said Oliver Marseille, PhD, chief technology officer of Hemovent and a co-founder of CircuLite (Heartware International) prior to co-founding Hemovent.
In 2019, the company receive the CE mark for the MOBYBOX System with the Master Controller and is currently in preparing a post market clinical follow-up trial.
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies
CirCode Biomed's IND application for HM2002 receives FDA clearance
CeleCor Therapeutics completes Phase 3 trial of new anti-platelet agent for heart attack
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
Ionis reports positive Phase 3 results for olezarsen in moderate hypertriglyceridemia
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment